Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Lambdalina** is a brand name for a topical cream containing **40 mg/g lidocaine**, used as a local anesthetic to numb the skin prior to procedures such as needle sticks, blood draws, laser hair removal, and minor dermatological interventions. Lidocaine acts by blocking sodium channels in nerve membranes, preventing the initiation and conduction of nerve impulses, thereby inducing reversible loss of sensation in the applied area. Developed and marketed primarily in Europe (e.g., Spain), it is applied in doses of 2-3g over 1-2 cm² for 60 minutes prior to use, with a maximum daily dose of 5g in adults.[1][2][3][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lambdalina.